VENUSREM Latest Share Price (VENUSREM)
TODAY IN ONE LINE
With a market cap of ₹2,232.62 Cr., it trades at a P/E of 19.22. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
VENUSREM flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Earnings GrowthEPS (TTM) grew by a solid 126.4% YoY
- ●High Capital EfficiencyROCE of 16.2% indicating pricing power
- ●Strong Return on EquityHealthy ROE of 15.5%
- ●Healthy Operating MarginsOPM is structurally strong at 17.6%
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.00x
- ●Positive Free Cash FlowFCF has been positive for 3 consecutive years
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Sales ContractionQuarterly sales dropped 0.0% YoY
- ●Rising Receivables vs SalesReceivables grew 23.8% outpacing sales growth of 7.7%
Latest VENUSREM News
What changed recently?
Recent events, corporate actions, and announcements.
VENUSREM valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for VENUSREM, framed against the sector median so the premium or discount is obvious at a glance.
VENUSREM trades at a P/E of 19.22× and P/B of 3.36×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
VENUSREM technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for VENUSREM — derived from the latest tape, not yesterday's close.
VENUSREM last traded at ₹1,796.7 with an intraday range of ₹1,715–₹1,880 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹1796.70| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 2209.47 | +412.77 | +22.97% |
| R3 | 2044.47 | +247.77 | +13.79% |
| R2 | 1962.23 | +165.53 | +9.21% |
| R1 | 1879.47 | +82.77 | +4.61% |
| PIVOT | 1797.23 | 0.53 | 0.03% |
| CURRENT | 1796.70 | — | — |
| S1 | 1714.47 | -82.23 | -4.58% |
| S2 | 1632.23 | -164.47 | -9.15% |
| S3 | 1549.47 | -247.23 | -13.76% |
| S4 | 1384.47 | -412.23 | -22.94% |
VENUSREM is trading Below CPR, indicating Bearishness
CPR is Narrower, suggesting likely for trending moves
Day's range: ₹–₹
Trading Above opening range, showing Bullishness
VENUSREM financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for VENUSREM — consolidated or standalone — with margins, YoY growth and key ratios inline.
VENUSREM reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹2,232.62 Cr. and reported EPS of ₹19.10.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 648 | 770 ▲ 18.8% |
| Sales Growth YoY %Derived | 7.72% | 18.79% |
| Other Income | 21 | 13 ▼ 40.0% |
| Total Income | 669 | 782 ▲ 16.9% |
| 379 | 387 ▲ 2.3% | |
| Gross ProfitDerived | 269 | 382 ▲ 42.0% |
| Gross Margin %Derived | 41.56% | 49.68% |
| 206 | 235 ▲ 14.3% | |
| EBITDA (Operating Profit)Derived | 64 | 147 ▲ 131.8% |
| OPM %Derived | 9.81% | 19.14% |
| 32 | 26 ▼ 20.9% | |
| Profit Before Tax (PBT) | 72 | 134 ▲ 86.8% |
| 24 | 31 ▲ 33.0% | |
| Effective Tax %Derived | 32.83% | 23.38% |
| Total Profit for Period | 45 | 103 ▲ 126.8% |
| Net Profit (Owner's PAT)Derived | 45 | 103 ▲ 126.8% |
| Net Profit Margin %Derived | 7.00% | 13.35% |
| PAT Growth YoY %Derived | 59.04% | 126.79% |
| Earnings Per Share (EPS ₹) | 33.90 | 76.89 ▲ 126.8% |
| Diluted Shares Outstanding (Cr) | 1 | 1 ▲ 0.0% |
| Other Comprehensive Income (Net of Tax) | -1 | 0 ▲ 101.5% |
| Total Expenses (incl. D&A & Interest) | 597 | 648 ▲ 8.5% |
| Material Cost % of RevenueDerived | 53.83% | 50.41% |
| Employee Cost % of RevenueDerived | 12.42% | 11.52% |
| Other Cost % of RevenueDerived | 19.33% | 19.02% |
| Interest Coverage (x)Derived | 586.14x | 3,040.25x |
| Period | Mar 2018 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 372 | 341 ▼ 8.3% | 548 ▲ 60.5% | 599 ▲ 9.2% | 556 ▼ 7.2% | 601 ▲ 8.3% | 648 ▲ 7.7% | 770 ▲ 18.8% | |
| Sales Growth YoY %Derived | — | — | 60.52% | 9.22% | -7.21% | 8.27% | 7.72% | 18.79% | |
| Other Income | 2 | 5 ▲ 135.4% | 20 ▲ 269.8% | 8 ▼ 57.7% | 10 ▲ 24.2% | 12 ▲ 12.2% | 21 ▲ 81.0% | 13 ▼ 40.0% | |
| Total Income | 375 | 347 ▼ 7.4% | 568 ▲ 63.7% | 607 ▲ 6.9% | 566 ▼ 6.8% | 613 ▲ 8.3% | 669 ▲ 9.1% | 782 ▲ 16.9% | |
205 | 174 ▼ 15.0% | 341 ▲ 95.5% | 385 ▲ 13.1% | 331 ▼ 14.1% | 355 ▲ 7.2% | 379 ▲ 6.7% | 387 ▲ 2.3% | ||
| Gross ProfitDerived | 167 | 167 ▼ 0.1% | 207 ▲ 24.0% | 213 ▲ 2.8% | 225 ▲ 5.3% | 247 ▲ 9.9% | 269 ▲ 9.1% | 382 ▲ 42.0% | |
| Gross Margin %Derived | 44.93% | 48.95% | 37.83% | 35.61% | 40.42% | 41.03% | 41.56% | 49.68% | |
128 | 126 ▼ 1.2% | 154 ▲ 21.5% | 151 ▼ 1.6% | 164 ▲ 8.8% | 187 ▲ 13.9% | 206 ▲ 9.9% | 235 ▲ 14.3% | ||
| EBITDA (Operating Profit)Derived | 39 | 41 ▲ 3.4% | 54 ▲ 31.7% | 62 ▲ 15.5% | 60 ▼ 3.1% | 60 ▼ 1.0% | 64 ▲ 6.6% | 147 ▲ 131.8% | |
| OPM %Derived | 10.60% | 11.95% | 9.81% | 10.38% | 10.84% | 9.91% | 9.81% | 19.14% | |
69 | 37 ▼ 47.2% | 72 ▲ 96.3% | 34 ▼ 52.6% | 33 ▼ 4.2% | 27 ▼ 18.6% | 32 ▲ 22.4% | 26 ▼ 20.9% | ||
| Profit Before Tax (PBT) | -28 | -8 ▲ 70.8% | 49 ▲ 704.3% | 36 ▼ 25.0% | 38 ▲ 4.2% | 45 ▲ 17.7% | 72 ▲ 60.9% | 134 ▲ 86.8% | |
3 | 2 ▼ 37.8% | -13 ▼ 772.7% | -4 ▲ 67.3% | 11 ▲ 363.2% | 16 ▲ 42.2% | 24 ▲ 46.0% | 31 ▲ 33.0% | ||
| Effective Tax %Derived | -11.48% | -24.45% | -27.21% | -11.85% | 29.95% | 36.17% | 32.83% | 23.38% | |
| Total Profit for Period | -31 | -10 ▲ 67.4% | 62 ▲ 717.8% | 41 ▼ 34.1% | 27 ▼ 34.8% | 28 ▲ 7.2% | 45 ▲ 59.0% | 103 ▲ 126.8% | |
| Net Profit (Owner's PAT)Derived | -31 | -10 ▲ 67.4% | 62 ▲ 717.8% | 41 ▼ 34.1% | 27 ▼ 34.8% | 28 ▲ 7.2% | 45 ▲ 59.0% | 103 ▲ 126.8% | |
| Net Profit Margin %Derived | -8.24% | -2.93% | 11.27% | 6.80% | 4.78% | 4.74% | 7.00% | 13.35% | |
| PAT Growth YoY %Derived | — | — | 717.77% | -34.07% | -34.76% | 7.25% | 59.04% | 126.79% | |
| Earnings Per Share (EPS ₹) | -24.87 | -8.10 ▲ 67.4% | 50.04 ▲ 717.8% | 30.47 ▼ 39.1% | 19.88 ▼ 34.8% | 21.32 ▲ 7.2% | 33.90 ▲ 59.0% | 76.89 ▲ 126.8% | |
| Diluted Shares Outstanding (Cr) | 1 | 1 ▲ 0.0% | 1 ▲ 0.0% | 1 ▲ 8.3% | 1 ▲ 0.0% | 1 ▲ 0.0% | 1 ▲ 0.0% | 1 ▲ 0.0% | |
| Other Comprehensive Income (Net of Tax) | 0 | -0 ▼ 237.2% | -0 ▲ 79.9% | -1 ▼ 491.6% | -7 ▼ 1094.0% | -1 ▲ 80.9% | -1 ▲ 46.9% | 0 ▲ 101.5% | |
| Total Expenses (incl. D&A & Interest) | 402 | 355 ▼ 11.8% | 519 ▲ 46.3% | 571 ▲ 9.9% | 528 ▼ 7.5% | 568 ▲ 7.7% | 597 ▲ 5.0% | 648 ▲ 8.5% | |
| Material Cost % of RevenueDerived | 55.00% | 49.33% | 63.48% | 63.81% | 57.21% | 57.24% | 53.83% | 50.41% | |
| Employee Cost % of RevenueDerived | 10.56% | 13.48% | 8.40% | 8.74% | 11.04% | 11.89% | 12.42% | 11.52% | |
| Other Cost % of RevenueDerived | 23.78% | 23.52% | 19.62% | 16.50% | 18.54% | 19.23% | 19.33% | 19.02% | |
| Interest Coverage (x)Derived | 0.16x | 0.66x | 1.42x | 59.42x | 96.21x | 352.77x | 586.14x | 3,040.25x |
VENUSREM segment analysis : revenue and profit mix.
Disclosed business segments at VENUSREM with their share of revenue and profit, switchable between consolidated and standalone reporting.
VENUSREM discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for VENUSREM.
Our AI distills the core fundamental drivers supporting VENUSREM, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
VENUSREM's investment case rests on 10 positive markers and 9 flagged concerns drawn from the latest reported filings.
What you're getting.
Zero debt-to-equity ratio indicates strong financial stability and low leverage.
Exceptional quarterly profit growth of 687.00% reflects strong operational performance.
Robust quarterly sales growth of 21.40% indicates increasing demand and market penetration.
Attractive P/E ratio of 11.01 suggests potential undervaluation compared to peers.
Diversified product portfolio across critical care and herbal medicine segments.
Key Risks.
Relatively low ROE (4.64%) and ROCE (11.10%) indicate scope for efficiency.
Absence of dividend yield (0.00%) may deter income-focused investors.
Stagnant 5-year EPS growth of 0.00% indicates lack of long-term earnings expansion.
Negative 5-year Free Operating Cash Flow CAGR of -0.42% is concerning.
Current stock price significantly below 52-week high suggests recent downtrend.
Flip Conditions.
Valuation risk. a P/E above 25 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Return-quality risk. ROE below 10% would indicate weaker capital compounding.
Income thesis breaks if the dividend is cut or yield falls below 0.28%.
VENUSREM peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — VENUSREM is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
VENUSREM chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for VENUSREM — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
VENUSREM delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for VENUSREM over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in VENUSREM stood at 56.1% of traded volume, against a 20-day average of 62.9%.
VENUSREM announcements: results, concalls, ratings, M&A.
Filings VENUSREM sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
VENUSREM files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 81 documents below.
Updates
Venus Remedies Limited has informed the Exchange regarding 'Intimation regarding change in Corporate Identification Number (CIN).'.
Trading Window
Venus Remedies Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations,…
Copy of Newspaper Publication
Venus Remedies Limited has informed the Exchange about Copy of Newspaper Publication
Copy of Newspaper Publication
Venus Remedies Limited has informed the Exchange about newspaper publication of notice to physical shareholders for transfer of physical shares as…
Updates
Venus Remedies Limited has informed the Exchange regarding Social Media Post on awareness on transfer of physical shares ''.
VENUSREM dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue VENUSREM has declared, sequenced by announce and record date.
VENUSREM corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About VENUSREM: business, sector, key facts.
What VENUSREM does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
VENUSREM operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: VENUSREM, BSE: 526953.
Venus Remedies Limited is a pharmaceutical company headquartered in Panchkula, India, operating both domestically and internationally. Their core business revolves around the research, development, manufacturing, and distribution of a wide array of pharmaceutical products.
The company's product portfolio spans a diverse range of therapeutic areas, catering to a broad spectrum of medical needs. These therapeutic areas include, but are not limited to: analgesics (pain relievers), antipyretics (fever reducers), anti-diabetics, antibiotics, antiemetics (anti-nausea medications), antivirals, cardiovascular medications, disinfectants and antiseptics, gastrointestinal therapies, hepatoprotective agents (liver protectants), hormone therapies, immunostimulants, iron supplements, muscle relaxants, neurological medications, oncology medications, respiratory medications, and anticoagulants (blood thinners).
Beyond conventional pharmaceuticals, Venus Remedies also maintains a significant presence in the herbal medicine market, offering a portfolio of products derived from natural sources. This demonstrates a commitment to providing diverse treatment options and potentially catering to a broader consumer base interested in alternative or complementary therapies.
Established in 1989, Venus Remedies has a history of nearly three and a half decades in the pharmaceutical industry. This longevity suggests a degree of stability and market experience, although the specific details of their market share and financial performance would require further information beyond the provided text.
In summary, Venus Remedies' business model is built upon a diversified product portfolio encompassing both conventional and herbal pharmaceuticals, targeting a wide array of therapeutic areas and serving both domestic and international markets. Their long operational history suggests established processes and infrastructure within the pharmaceutical industry.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- AAREY DRUGS & PHARM (AAREYDRUGS) Share PricePeer
- AARTI DRUGS (AARTIDRUGS) Share PricePeer
- AARTI PHARMALABS (AARTIPHARM) Share PricePeer
- AJANTA PHARMA (AJANTPHARM) Share PricePeer
- AKUMS DRUGS AND PHARMA L (AKUMS) Share PricePeer
- Stocks near 52-week high (breakout watch)Screener
- Breakout Trader strategy playbookStrategy
- Other undervalued NSE stocksScreener
- Quality + Value Portfolio strategyStrategy
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about VENUSREM (VENUSREM).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of VENUSREM (VENUSREM)?
The current share price of VENUSREM (VENUSREM) is ₹1,796.70. Today, the stock has gained by ₹0.60 (0.03%), trading in a range of ₹1,715.00 to ₹1,880.00. The stock opened at ₹1,877.00 with a trading volume of 1,16,523 shares.
02Is VENUSREM stock a good investment for long-term?
VENUSREM can be considered for long-term investment based on several factors. The company has a market capitalization of ₹2,232.62 Cr., P/E ratio of 19.22, ROE of 15.49%, and ROCE of 16.2%. The dividend yield stands at 0.56%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of VENUSREM stock?
The 52-week high price of VENUSREM (VENUSREM) is ₹1,880.00, while the 52-week low is ₹432.10. Currently trading at ₹1,796.70, the stock is 315.81% above its 52-week low and 4.43% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy VENUSREM stock at the current price?
Whether to buy VENUSREM stock at ₹1,796.70 depends on multiple factors. The stock is currently trading with a P/E ratio of 19.22 and P/B ratio of 3.36. Today's performance shows a gain of 0.03%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of VENUSREM and when is the next dividend?
VENUSREM offers a dividend yield of 0.56%, which means for every ₹100 invested at the current price of ₹1,796.70, you can expect to receive approximately ₹0.56 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of VENUSREM?
VENUSREM's key financial metrics include: P/E Ratio: 19.22, P/B Ratio: 3.36, ROE: 15.49%, ROCE: 16.2%, Dividend Yield: 0.56%, EPS: ₹19.10, Book Value: ₹496.56, and Debt-to-Equity: 0. The company's market cap stands at ₹2,232.62 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is VENUSREM stock performing today in the market?
VENUSREM stock opened at ₹1,877.00 and is currently trading at ₹1,796.70, showing a gain of ₹0.60 (0.03%). The intraday high is ₹1,880.00 and low is ₹1,715.00. The trading volume stands at 1,16,523 shares, indicating moderate market participation today.
08What is the P/E ratio of VENUSREM and what does it indicate?
VENUSREM has a Price-to-Earnings (P/E) ratio of 19.22, which means investors are willing to pay 19.22 for every ₹1 of earnings. With an EPS of ₹19.10, this P/E ratio indicates moderate valuation in line with market standards. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about VENUSREM (VENUSREM) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.